POIT BIOP
Presenter SpeechYue-Wen Zhu (Analysts)Good afternoon, everyone. I'm Charles Zhu, one of the se...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Sector
-